Comparing the current results to its competitors, Scinai Immunotherapeutics Ltd reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Scinai Immunotherapeutics Ltd's competitors' average revenue growth of 5.06 %, achieved in the same quarter.
Scinai Immunotherapeutics Ltd, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 97.27 %
Scinai Immunotherapeutics Ltd's Comment on Competition and Industry Peers
The competitive environment for the company is influenced by factors including regulatory approvals, demand, demonstration of safety and efficacy, strategic partnerships, marketing capabilities, manufacturing quality, and pricing and reimbursement decisions. Biosimilar products may compete with the company's offerings, with competition affected by evolving FDA guidance, regulatory practices, and litigation. Competitors may pursue approval of biologics through full Biologics License Applications (BLAs) supported by independent data rather than the abbreviated biosimilar pathway, potentially circumventing regulatory exclusivity. Regulatory exclusivity frameworks vary between the United States and the European Union, with ongoing legislative reforms impacting the timing and scope of competition. Delays or failures in clinical trials could enable competitors to market products first, reducing the company's commercial opportunities. Clinical trials involve significant costs, time, and regulatory oversight from authorities such as the FDA and EMA. Competitors may develop alternative products that could render the company's candidates obsolete, or the company's candidates may fail due to safety, efficacy, production, or regulatory acceptance challenges.
Opthea Limited operates as a clinical stage biotechnology company, primarily focused on the development of novel therapies for the treatment of eye diseases. The company pursues its business model by leveraging its expertise in the discovery and development of innovative therapeutics, while collaborating with strategic partners and conducting clinical trials to bring its products to market.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Sources:
Scinai Immunotherapeutics Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Scinai Immunotherapeutics Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
